Durect Corporation (DRRX) : Traders are bullish on Durect Corporation (DRRX) as it has outperformed the S&P 500 by a wide margin of 50.16% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 9.68%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 9.6% in the last 1 week, and is up 55.2% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 32.6% and the 50-Day Moving Average is 45.38%. DURECT Corporation is up 44.78% in the last 3-month period. Year-to-Date the stock performance stands at -12.22%.
Durect Corporation (NASDAQ:DRRX): stock turned positive on Friday. Though the stock opened at $1.88, the bulls momentum made the stock top out at $1.95 level for the day. The stock recorded a low of $1.82 and closed the trading day at $1.94, in the green by 4.30%. The total traded volume for the day was 1,091,943. The stock had closed at $1.86 in the previous days trading.
Durect Corporation is a specialty pharmaceutical company. The Company is focused on the development of pharmaceuticals based on its drug delivery technology platforms, chemical entities derived from its Epigenomic Regulator Program, and its engagement in drug development. Its research and development programs fall into one of two categories: Drug Delivery Programs, in which it applies its formulation and technologies to pharmaceutical ingredients, and New Chemical Entities derived from its Epigenomic Regulator Program, in which it discovers and develops molecules. It also manufactures and sells osmotic pumps and biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products. Its product pipeline consists of seven investigational drug candidates in clinical development: REMOXY (ORADUR-Oxycodone), POSIDUR (SABER-Bupivacaine), ELADUR (TRANSDUR-Bupivacaine), Relday, ORADUR-ADHD, ORADUR-Opioid and SABER-based ophthalmic.